David D. Chang - Mar 15, 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Signature
/s/ Veer Bhavnagri, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Mar 15, 2022
Transactions value $
-$180,879
Form type
4
Date filed
3/17/2022, 05:59 PM
Previous filing
May 26, 2021
Next filing
Mar 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Sale -$181K -23.6K -1.02% $7.65 2.29M Mar 15, 2022 Direct F1, F2, F3
holding ALLO Common Stock 1.2M Mar 15, 2022 See footnote F4
holding ALLO Common Stock 856K Mar 15, 2022 See footnote F5
holding ALLO Common Stock 856K Mar 15, 2022 See footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.59 to $7.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 Includes 1021 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program.
F4 Securities held in the name of the Chang 2006 Family Trust.
F5 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F6 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.